A research team has developed a reliable and economical method for studying proteins with sugar molecules attached to them in blood and tissue samples. The method uses commercially available magnetic particles and has the potential to aid in disease diagnosis and treatment.
A study reveals that H5N1 bird flu causes severe infection in cow udders instead of lungs, and identifies a specific glycan receptor subtype as the key to its unusual behavior. This discovery provides a new way to predict the virus's next host jump and potential disease manifestation.
Researchers at the University of Gothenburg discovered that grey seal milk contains approximately 33% more sugar molecules than breast milk, including unique and powerful compounds against disease-causing bacteria. These findings could lead to improved infant formula and potential applications in human health.
Researchers investigated GnT-V, a cancer-related glycosylation enzyme, and found its selectivity relies on protein structure and subcellular trafficking. Two enzymes, metalloproteases, were identified as major substrates in the kidney.
Researchers mapped dynamic glycosylation patterns in rat serum proteins, revealing distinct cell-type-specific profiles. Female rats exhibited pronounced daily fluctuations in sugar structures, suggesting regulation by hormonal and circadian cycles.
Researchers identified hundreds of hidden binding partners for a blood protein receptor, revealing links to organ dysfunction and increased sepsis risk. The study found that Mrc1's absence led to the accumulation of mannosylated proteins, which disrupted normal physiology and function.
Researchers have reexamined the Ashwell-Morell receptor's functions using innovative glycoengineering techniques, clarifying its roles in sepsis and inflammation control. The study reveals that the receptor can bind to a specific type of protein glycan chain, which was previously thought to be incompatible with binding.
Researchers have created an 'immune cell map' that reveals the origin of neutrophils' subcellular response to microbes. The study found that a specific type of glycoprotein is responsible for the restricted subcellular origin, and this discovery may lead to refined personalized immune responses.
Researchers have identified a novel enzyme that catalyzes the formation of glycosidic bonds in complex sugar moieties. The discovery provides fresh insights into carbohydrate metabolism and offers a breakthrough for the synthesis of sugar chains, which play key roles in various biological processes.
GlycoNet will deliver reliable vaccine information to Canadians through interactive digital campaigns and K-12 classroom tools, supporting science literacy skills. The grant aims to promote evidence-based decision-making on vaccines across the country.
GlycoNet invests $1.3 million in new sugar research projects to tackle unmet needs in national healthcare, aiming to deliver made-in-Canada solutions and protect Canadians' lives. The funding supports various projects, including the development of gene therapies and enzymatic tools for blood supply innovation.
GlycoNet has secured a three-year investment of $16.3 million through the Canadian Glycomics Network to accelerate carbohydrate-based healthcare treatments, vaccines, and technologies. The network aims to improve the quality of life of Canadians by delivering solutions to important health issues.
Five Alberta-based projects have received funding from GlycoNet's Alberta Partnership Program to advance research on various health issues. The projects aim to develop new treatments for diseases such as Alzheimer's, cancer, and inflammatory intestinal diseases.
GlycoNet has awarded $885,000 in grants to seven research projects across Canada focusing on improving health outcomes for conditions such as heart disease, infections, cancer, and diabetes. The projects aim to develop accessible solutions through glycomics research.
GlycoNet researchers Matthew Macauley and John Klassen are developing a strategy to identify the molecular identity of sugars interacting with CD33 protein, strongly implicated in Alzheimer's disease. This approach may lead to therapeutic targets or diagnostic tools for preventing or treating the disease.
GlycoNet has awarded $3.5 million to researchers across Canada to explore glycomics and its impact on human health. The grants will support research into Parkinson's disease, Alzheimer's, drug-resistant fungal infections, and other areas.
Researchers at Griffith University have discovered a potential new therapeutic treatment for mosquito-borne alphavirus infections, including Ross River Virus and Chikungunya Virus. Pentosan polysulfate sodium (PPS) has shown promising results in treating acute and chronic disease manifestations of alphavirus infections.
A breakthrough discovery has been made in developing a vaccine for middle ear infections by identifying the molecular switch that controls a 'chameleon' bacteria. Researchers have found that this switch allows Haemophilus influenzae to adapt and evade the immune system, making it difficult to develop an effective vaccine.
Researchers at Griffith University have created a groundbreaking combination vaccine that combines the protein SpyCEP with J8-DT to combat Streptococcus A infections. The vaccine shows promise in preventing deadly complications of the infection, including rheumatic heart disease.
Research by Griffith University's Institute for Glycomics has made a significant breakthrough in tackling the human parainfluenza virus, which causes respiratory infections such as croup and pneumonia. The team has demonstrated how the virus engages specific sugars to spread and cause infection.
Researchers have advanced understanding of rotavirus's attack on human cells through carbohydrate receptors, providing clues for anti-rotaviral drugs. The discovery has implications for childhood susceptibility to rotavirus disease and offers potential for new vaccine development strategies.
New anti-viral drugs and vaccines are urgently needed to combat Human parainfluenza virus, a leading cause of respiratory tract disease in young children. Researchers have identified potent inhibitors that block both cell entry and virion release, offering hope for treatment and prevention.
Researchers have discovered a key enzyme involved in O-glycosylation of LDLR, a receptor protein responsible for absorbing bad cholesterol. The study provides new insights into the functional impact of glycosylation on cholesterol levels.
Researchers discovered novel approach using llama-derived antibodies to control deadly C. difficile infections by targeting the pathogen's toxin proteins. This breakthrough provides opportunities for creating more effective treatments.
Researchers at Griffith University have discovered how Neisseria meningitidis attaches to human airways, a key step in the development of invasive disease. This breakthrough understanding may lead to the identification of new risk factors and treatment procedures.
Researchers have identified a carbohydrate modification on leukaemic cells that can be targeted to eradicate cancer. The study, published in Journal of Experimental Medicine, offers hope for new treatment options against drug-resistant forms of acute lymphoblastic leukaemia.
Griffith University's Institute for Glycomics has launched a human trial for a Streptococcus A vaccine, targeting a protein on the surface of Strep A bacteria. The year-long trial aims to ensure the vaccine's safety and effectiveness in preventing rheumatic fever, particularly in remote Aboriginal communities with high infection rates.
Researchers at Emory University School of Medicine have adapted gene chip microarray technology to the study of glycans, using an approach called 'shotgun glycomics.' This technique allows for the separation and analysis of thousands of glycans, enabling researchers to test what sticks to them. The method has been used to identify a mo...
Researchers at the University of New Hampshire Glycomics Center have identified a specific carbohydrate structure that confers anti-inflammatory activity to a glycoprotein antibody. This discovery may lead to improved treatment options for autoimmune diseases such as lupus and rheumatoid arthritis.
The Consortium for Functional Glycomics, a group of scientists from around the world, has received a $40.7 million grant to unravel the mysteries of carbohydrates. The team plans to use this funding to uncover new biology and translate discoveries into treatments for disease.